NEW YORK–(BUSINESS WIRE)–Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novelNEW YORK–(BUSINESS WIRE)–Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel

MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference

NEW YORK–(BUSINESS WIRE)–Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that Rob Barrow, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 2:15 p.m. PT.

“It is a privilege to participate in the J.P. Morgan Healthcare Conference as we continue to share the progress MindMed is making to forge a new era of psychiatry,” said Rob Barrow, Chief Executive Officer. “The conference provides a meaningful opportunity to engage with the investment community as we prepare for a defining year ahead with three anticipated Phase 3 topline readouts, advancing toward potential FDA submissions in two of the largest psychiatry markets, GAD and MDD.”

A live audio webcast will be available to investors and other interested parties and can be accessed here.

The audio webcast replay will be available 24 hours after the webcast and active on MindMed’s website for 30 days.

About MindMed

MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates targeting neurotransmitter pathways that play key roles in brain health.

MindMed trades on NASDAQ under the symbol MNMD.

Contacts

For further information, please contact:

Investors:
Gitanjali Jain

VP, Head of Investor Relations

ir@mindmed.co

Media:
media@mindmed.co

Market Opportunity
PoP Planet Logo
PoP Planet Price(P)
$0.01718
$0.01718$0.01718
-1.15%
USD
PoP Planet (P) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

BFX Presale Raises $7.5M as Solana Holds $243 and Avalanche Eyes $1B Treasury — Best Cryptos to Buy in 2025

BFX Presale Raises $7.5M as Solana Holds $243 and Avalanche Eyes $1B Treasury — Best Cryptos to Buy in 2025

BFX presale hits $7.5M with tokens at $0.024 and 30% bonus code BLOCK30, while Solana holds $243 and Avalanche builds a $1B treasury to attract institutions.
Share
Blockchainreporter2025/09/18 01:07
Trading time: Tonight, the US GDP and the upcoming non-farm data will become the market focus. Institutions are bullish on BTC to $120,000 in the second quarter.

Trading time: Tonight, the US GDP and the upcoming non-farm data will become the market focus. Institutions are bullish on BTC to $120,000 in the second quarter.

Daily market key data review and trend analysis, produced by PANews.
Share
PANews2025/04/30 13:50
BlackRock boosts AI and US equity exposure in $185 billion models

BlackRock boosts AI and US equity exposure in $185 billion models

The post BlackRock boosts AI and US equity exposure in $185 billion models appeared on BitcoinEthereumNews.com. BlackRock is steering $185 billion worth of model portfolios deeper into US stocks and artificial intelligence. The decision came this week as the asset manager adjusted its entire model suite, increasing its equity allocation and dumping exposure to international developed markets. The firm now sits 2% overweight on stocks, after money moved between several of its biggest exchange-traded funds. This wasn’t a slow shuffle. Billions flowed across multiple ETFs on Tuesday as BlackRock executed the realignment. The iShares S&P 100 ETF (OEF) alone brought in $3.4 billion, the largest single-day haul in its history. The iShares Core S&P 500 ETF (IVV) collected $2.3 billion, while the iShares US Equity Factor Rotation Active ETF (DYNF) added nearly $2 billion. The rebalancing triggered swift inflows and outflows that realigned investor exposure on the back of performance data and macroeconomic outlooks. BlackRock raises equities on strong US earnings The model updates come as BlackRock backs the rally in American stocks, fueled by strong earnings and optimism around rate cuts. In an investment letter obtained by Bloomberg, the firm said US companies have delivered 11% earnings growth since the third quarter of 2024. Meanwhile, earnings across other developed markets barely touched 2%. That gap helped push the decision to drop international holdings in favor of American ones. Michael Gates, lead portfolio manager for BlackRock’s Target Allocation ETF model portfolio suite, said the US market is the only one showing consistency in sales growth, profit delivery, and revisions in analyst forecasts. “The US equity market continues to stand alone in terms of earnings delivery, sales growth and sustainable trends in analyst estimates and revisions,” Michael wrote. He added that non-US developed markets lagged far behind, especially when it came to sales. This week’s changes reflect that position. The move was made ahead of the Federal…
Share
BitcoinEthereumNews2025/09/18 01:44